BIT's 18th Annual Congress of International Drug Discovery Science and Technology (IDDST-2020)
Scientific Program

Day 1 | Day 2 | Day 3

 

Keynote Forum

Day 1: Morning, July. 15, 2021

Moderator

Dr. Mattias von Herrath, Vice President/Head NovoNordisk; Professor/Director of the Diabetes Center, La Jolla Institute, USA

Time

Speeches and Speakers

09:00-09:05

Chair's Introduction

09:05-09:30

Title: Tankyraseinhibitors: Evidence for Therapeutic Potential in Immuno-oncology

Dr. Luc Van Hijfte, SVP Medicinal Chemistry, Symeres, the Netherlands

09:30-09:55

Title: TBD

Dr. Mattias von Herrath, Vice President/Head NovoNordisk; Professor/Director of the Diabetes Center, La Jolla Institute, USA

09:55-10:20

Title: Nanoparticles for Gene and Drug Delivery: Applying Light Scattering to Screening and Characterization

Dr. Daniel Some, Principal Scientist, Wyatt Technology Corporation, USA

10:20-10:45

Title: The Role of ABC Membrane Transporters in Personalized Diagnostics and Drug Treatment

Dr. Balazs Sarkadi, Professor, Semmelweis University, Hungary

10:45-11:10

Title: Next Generation T Cell Therapy Products Partnering with Pfizer – Introduction to Emerging Science & Innovation

Dr. Uwe Schoenbeck, Senior Vice President & Chief Scientific Officer, Worldwide R & D, Pfizer, USA

11:10-11:35

Title: New Innovative Ways to Enhance Treatment Targeting and Individualization: The Complementary Use of Predicting Modeling and Machine Learning in the Field of Diabetes and Metabolic Disorders

Dr. Zsolt Bosnyak, VP, Global Medical Head Diabetes, Sanofi, France

 

Session 211: Pharmacogenetics, Pharmacogenomics and Precision Medicine 

Day 1: Afternoon, July. 15, 2021

Chair

Dr. Godefridus J Peters, Professor in Pharmacology of Cytostatics, Amsterdam University Medical Centers, the Netherlands

Co-Chair  Dr. Hongtao Xiao, Professor, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, China

Time

Speeches and Speakers

13:30-13:35

Chair's Introduction

13:35-14:05

Keynote Speech

Title: Personalized and Precision Medicine (PPM) as a Unique Healthcare Model to be Set Up via Translational Applications and Upgraded Business Modeling to Secure the Human Healthcare, Wellness and Biosafety

Dr. Sergey Suchkov, Professor, Director, Center for Personalized Medicine, I.M. Sechenov First Moscow State Medical University, Russia

14:05-14:30

Title: The Role of Pharmacogenetics and Drug Discovery

Dr. Godefridus J Peters, Professor in Pharmacology of Cytostatics, Amsterdam University Medical Centers, the Netherlands

14:30-14:55

Title: Testing Complex Activity Profiles of Human Immune Cell using a Highly Standardised Bed-side Whole Blood Culture Model

Dr. Manfred Schmolz, CEO/CSO, HOT Screen GmbH, Germany

14:55-15:20

Title: The Influence of MTHFR Genetic Polymorphisms on Adverse Reactions after Methotrexate in Patients with Hematological Malignancies

Dr. Hongtao Xiao, Professor, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, China

15:20-15:30

Coffee Break

  15:30-15:55

Title: Optimized and Fully Characterized Drugs Together with Disease Understanding: De-risking Clinical Development

Dr. Charlotte Kopitz, EVP, Head of Therapeutic Research, Nuvisan Pharma Services Group, Germany

  15:55-16:20

Title: Precision Medicine at the Interface of Translational Research and Systems Medicine

Dr. Kristel Van Steen, Professor, University of Liege/KU Leuven, Belgium

  16:20-16:45

Title: Disease Modeling of Heart Failure: Rare Diseases and SARS-CoV-2 Infection

Dr. Tetsuro Wakatsuki, Chief Scientific Officer, InvivoSciences, Inc., USA

  16:45-17:10

Speech Opportunity Available
Abstract and Biography: Submit Here

 

Session 221: Innovative Drug Discovery Technology

Day 1: Afternoon, July. 15, 2021

Chair

Dr. Alexey RAK, Director of Bio Structure and Biophysics, Sanofi R&D, France

  Co-chair
Dr. Barry Morgan, CSO, Hitgen Ltd., USA

Time

Speeches and Speakers

13:30-13:35

Chair's Introduction

13:35-13:55

Title: TBD

Dr. Alexey RAK, Director of Bio Structure and Biophysics, Sanofi R&D, France

13:55-14:15

Title: Effective Hit Discovery Strategies for Unlocking Challenging Soluble and Membrane Targets

Dr. Tom Mander, Chief Operating Officer, Domainex Ltd, UK

14:15-14:35

Title: Cold Chain Options for Cryopreservation and Transport of Natural and Bioengineered Tissues

Dr. Kelvin Brockbank, Chief Executive Officer, Tissue Testing Technologies LLC, USA

14:35-14:55

Title: Assays, Biophysics and Structural Biology towards Drugs with Innovative Inhibition Mode

Dr. Lars Neumann, Director Assays, Biophysics & Screening, Proteros biostructures GmbH, Germany

  14:55-15:15

Speech Opportunity Available
Abstract and Biography: Submit Here

15:15-15:30

Coffee Break

15:30-15:50

Title: 25 Years of DNA Encoded Chemistry: Managing serendipity in Pre-clinical Small Molecule Drug Discovery

Dr. Barry Morgan, CSO, Hitgen Ltd., USA

15:50-16:10

Title: Rapid Development of Nano-formulations from Screening to Production Combining Dual Centrifugation DELTAVITA 1 and Wet Agitator Bead Milling
Dr. Stefan Mende, Manager Techn + Scientific Communication/Sales, NETZSCH Vakumix GmbH, Germany

16:10-16:30

Title: Machine Learning Enabled Epitope Selective Antibody Discovery: Epitopes are the Foundation of Efficacy

Dr. Isaac Bright, Chief Executive Officer, RubrYc Therapeutics, Inc, USA

  16:30-16:50

Title: AlgoLight, A Photobioreactor Platform for Production of Microalgae-based Biopharmaceuticals

Dr. Jean Francois Jenck, Business Head,  Algolight, France

  16:50-17:10

Title: Accelerated Protein Development with Integrated Cell Free Expression, Purification, and Bioconjugation, Evaluated with Time-gated Raman

Dr. Marco G Casteleijn, Senior Scientist, VTT Technical Research Centre of Finland Ltd., Finland

 

Session 311: Cancer Drug Targets  

Day 1: Afternoon, July. 15, 2021

Chair

Dr. Laszlo Takacs, Member of the Hungarian Academy of Sciences, Laboratory of Monoclonal Antibody Proteomics, Department of Human Genetics, University of Debrecen, Hungary

Time

Speeches and Speakers

13:30-13:35

Chair's Introduction

13:35-14:00

Title: Epitome Level Screening Delivers New Drug Targets beyond Proteins

Dr. Laszlo Takacs, Member of the Hungarian Academy of Sciences, Laboratory of Monoclonal Antibody Proteomics, Department of Human Genetics, University of Debrecen, Hungary

14:00-14:25

Title: EGFR Inhibitors Update, Past present and Future

Dr. Irina Veytsman, Director of Hematology/Oncology Department, Washington Hospital Center, USA

14:25-14:50

Speech Opportunity Available
Abstract and Biography: Submit Here

14:50-15:15

Title: Targeting Human G-quadruplex Formed by Telomeric DNA and C9orf72 Hexanucleotide Repeats

Dr. Guang Zhu, Professor, The Hong Kong Univ. of Sci. and Tech., Hong Kong, China

15:15-15:30

Coffee Break

15:30-15:55

Title: Breaking Steroid Resistance by Targeted Compounds in Pediatric T-cell Acute Lymphoblastic Leukemia

Dr. Jules P. P. Meijerink, Principal Investigator, Princess Maxima Center for Paediatric Oncology, the Netherlands

15:55-16:20

Title: Arsenic Trioxide is Effective in Treating T-ALL and Synergistic Effect when Combined with Ruxolitinib

Dr. Sin Chun Fung, Assistant Professor, University of Hong Kong, Hong Kong, China

16:20-16:45

Title: The Role of TGFb-regulated microRNAs and LIN28B in Pancreatic Adenocarcinoma Progressions

Dr. Leandro Castellano, Honorary Senior Lecturer, University of Sussex, UK

16:45-17:10

Title: Novel Identified Key Factor of Angiogenesis

Dr. Zhaoli Zhou, Professor, Shanghai University of Medicine and Health Sciences, China

 

Session 321: Open Innovation in Drug Discovery

Day 1: Afternoon, July. 15, 2021

Chair

Dr. Florian Montel, Head of opnMe.com & CNS Project Leader, Boehringer Ingelheim, Germany

Time

Speeches and Speakers

13:30-13:35

Chair's Introduction

13:35-14:00

Title: TBD

Dr. Yoshinori Ikeura, CEO, Axcelead Drug Discovery Partners, Inc., Japan

14:00-14:25

Title: opnMe.com, The Boehringer Ingelheim Open Innovation Portal to Reach out to New Biology: 2 years of Experience and Perspectives for the Next 3 Years

Dr. Florian Montel, Head of opnMe.com & CNS Project Leader, Boehringer Ingelheim, Germany

14:25-14:50

Speech Opportunity Available
Abstract and Biography: Submit Here

14:50-15:15

Title: MAPK Cascade as a Drug Target for the Prevention of Adhesive Disease

Dr. Mikhail Shurygin, Research Director, Pharmasyntez, Russia

15:15-15:30

Coffee Break

 

Session 411: Cancers/Tumors

Day 1: Afternoon, July. 15, 2021

Chair

Dr. Luana Pesco Koplowitz, Chief Medical & Scientific Officer, DUCK FLATS Pharma, USA

 Co-Chair   Dr. Hidemitsu Nakagawa, President, Nozaki Tokushukai Hospital, Japan

Time

Speeches and Speakers

13:30-13:35

Chair's Introduction

13:35-13:55

Title: Radioactive Tracer Technology Applied to Clinical Pharmacology -a Historical Review based on Personal Experiences in Japan with Future Perspectives

Dr. Yasuhito Sasaki, Director, Research Center for Radiation Oncology, Shonankamakura General HospitalAffiliated Clinical Research Center; Visiting Professor, Graduate School of Yokohama City University, Japan

13:55-14:15

Title: Chemotherapeutic Treatment of Infants with Cancer: Challenges and Opportunities

Dr. Luana Pesco Koplowitz, Chief Medical & Scientific Officer, DUCK FLATS Pharma, USA

14:15-14:35

Title: Melatonin as an Antioxidant and Anti-cancer Agent: Directing it to the Mitochondria

Dr. Russel J Reiter, Professor, UT Heath, USA

  14:35-14:55

Title: Correlation of in Situ Oxazolidine Formation with Highly Synergistic Cytoxicity and DNA Cross-Linking in Cancer Cells from Combination of Doxorubicin and Formaldehyde

Dr. Ben Barthel, Scientist, University of Colorado, USA

  14:55-15:15

Speech Opportunity Available
Abstract and Biography: Submit Here

15:15-15:30

Coffee Break

15:30-15:50

Title: Intrathecal Sodium Butyrate for Malignant Brain Tumors and Lleptomeningeal Metastasis of Malignant Tumors-experimental Research and Clinical Trial

Dr. Hidemitsu Nakagawa, President, Nozaki Tokushukai Hospital, Japan

15:50-16:10

Title: TBD

Dr. Robert Huigens, Assistant Professor, University of Florida, USA

16:10-16:30

Title: Methylglyoxal: A Non Toxic and Potent Therapeutic Agent for Triple Negative Breast Cancer

Dr. Manju Ray, Professor, Department of Biophysics, Bose Institute, India 

16:30-16:50

Title:  The Concern and Prospective between Precision Medicine and Traditional Chinese Medicine

Dr. Tsai-ju Chien, Professor, Department of Medicine, National Yang Ming Medical College, Taiwan

  16:50-17:10

Title:  Aurora Kinase A Inhibitor (VX 680) Inhibits Cell Migration, Invasion, Proliferation and Viability and Promotes Cell Apoptosis in Human Prostate Cancer (PC3) Cells

Dr. Ahmad Al-Azayzih, Assistant Professor, United Arab Emirates University, Al Ain, United Arab Emirates

 

Session 421: Immunotherapy

Day 1: Afternoon, July. 15, 2021

Chair

Dr. Barbara Metzler, Head of Biology, Topas Therapeutics GmbH, Germany

 Co-Chair   Dr. Erminia Massarelli, Associate Professor, City of Hope, USA

Time

 

13:30-13:35

Chair's Introduction

13:35-14:00

Keynote Speech

Title: NKTR-255: A Potent NK and CD8 Memory T cell Mobilizer

Dr. Loui Madakamutil, VP, Head of Discovery, Nektar Therapeutics, USA

14:00-14:25

Title: Aviscumine-Another Immunotherapeutic Principle for The Treatment of Cancer

Dr. Hans Lentzen, VP Strategy and Innovation, LioniX International BV, the Netherlands

14:25-14:50

Title: The Use of Liver-targeting Nanoparticles to Induce Antigen-specific Immune Regulation

Dr. Barbara Metzler, Head of Biology, Topas Therapeutics GmbH, Germany

14:50-15:15

Speech Opportunity Available
Abstract and Biography: Submit Here

15:15-15:30

Coffee Break

15:30-15:55

Title: Bispecific T-Cell Engagers: Overview of Amgen‘s BiTE® Pipeline

Dr. Benno Rattel, Executive Director, Nonclinical Development, Amgen Research, Germany

15:55-16:20

Title: Novel Approach with Immunotherapy Combinations in Head and Neck and Non-small Cell Lung Cancers

Dr. Erminia Massarelli, Associate Professor, City of Hope, USA

16:20-16:45

Title: The Deep Impact of Translational Sciences in CAR T Cell Therapy Advancement

Dr. Jan Joseph (Jos) Melenhorst, Professor of Pathology & Laboratory Medicine; Director, Parker Institute for Cancer Immunotherapy Biomarker Program, University of Pennsylvania, USA

16:45-17:10

Title: Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms

Dr. Li Zhang, Professor and Senior Scientist, Toronto General Hospital Research Institute, University Health Network, University of Toronto, Canada

  

 

 



© 2003-2021 All rights reserved by BIT Congress
Contact Us: Email:Irene@iddst.com
Company Name: NOVA SILK ROAD SARL, Company Address: 37 rue des Mathurins, Paris, France